Anthony Mato

Trials

Studies that name Anthony Mato as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:18 UTC. Open this list on ClinicalTrials.gov

• N/A
  NCT04694560 · A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

  Memorial Sloan Kettering Cancer Center · withdrawn · CLL, SLL, CLL/SLL · principal investigator
• N/A
  NCT02993536 · Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab

  Abramson Cancer Center at Penn Medicine · withdrawn · Chronic Lymphocytic Leukemia · principal investigator
• Ph2
  NCT02742090 · Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

  TG Therapeutics, Inc. · terminated · Chronic Lymphocytic Leukemia · study chair
• Ph2
  NCT01241786 · Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL

  Hackensack Meridian Health · terminated · Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 22:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.